课题基金 / 基金详情

项目摘要

项目成果

Mengxiao Yu的其他基金

相似基金

相关文献

中文摘要
翻译
总结 系统性红斑狼疮(SLE)或狼疮是一种自身免疫性疾病, 全世界有500多万人,其中包括150万美国人。近60%的患者 会发展成狼疮性肾炎,导致肾衰竭。因此,其财政负担, 个别病人每年可达7万美元,比许多其他疾病高得多, 肾移植狼疮性肾炎的早期治疗可以显著减缓或 甚至阻止疾病发展到肾衰竭,蛋白尿,我们目前的黄金标准, 狼疮性肾炎的早期诊断有哪些? 虽然新的生物标志物或外源性肾功能标志物正在开发或测试中, 狼疮性肾炎早期诊断的临床试验,其敏感性和准确性是可比的 与蛋白尿有关。因此,即使在今天,蛋白尿仍然是黄金标准, 对狼疮肾损害的早期检测和准确监测的强烈需求尚未得到满足 患者为了解决这一未满足的需求,ClearNano Inc.正在开发一种测试代理, “ClearGold”可以用来检测狼疮肾炎更早,更准确地比 蛋白尿。在本申请中,我们旨在解决两个关键问题:(1)该方法的准确性如何 狼疮性肾炎的早期诊断方法有哪些? 与小鼠模型中的蛋白尿比较。成功将验证竞争力 ClearGold在狼疮肾损害早期检测中优于蛋白尿 小鼠模型,为“ClearGold”的临床转化奠定了坚实的基础。 通过这些研究,我们认为,长期以来在肾脏疾病的早期检测方面的挑战, 狼疮性肾炎的损害最终可以用我们的“ClearGold”测试剂来解决, 这意味着16亿美元的市场机会。
英文摘要
Summary Systemic lupus erythematosus (SLE) or lupus is an autoimmune disease that impacts more than 5 million people worldwide, including 1.5 million Americans. Nearly 60% of these patients will develop lupus nephritis, which can cause kidney failure. As a result, its financial burden to individual patient can reach $70,000/year, much higher than many other diseases because of kidney transplantation. Although early treatment of lupus nephritis can significantly slow down or even prevent the disease progression to kidney failure, proteinuria, our current gold standard for screening lupus patients, is not sensitive and accurate enough for early detection of lupus nephritis. While new biomarkers or exogenous renal function markers are being developed or tested in clinical trials for early diagnosis of lupus nephritis, their sensitivity and accuracy are comparable to those of proteinuria. As a result, even today, proteinuria remains the gold standard and there are strong unmet needs for early detection and accurate monitoring of kidney damages in the lupus patients. To address this unmet need, ClearNano Inc. is developing a test agent, named “ClearGold” that can be used to detect lupus nephritis much earlier and more accurately than proteinuria. In this application, we aim to address two key questions: (1) How accurate this method is in detection of lupus nephritis; (2) How early this method can identify lupus nephritis in comparison with proteinuria in the mouse model. The success will validate the competitive advantages of ClearGold over proteinuria in the early detection of kidney damages in the lupus mouse model, which will lay down a solid foundation for clinical translation of “ClearGold”. Through these studies, we believe that a long-standing challenge in the early detection of kidney damages in the lupus nephritis can be eventually addressed with our “ClearGold” test agent, which represents a $1.6 Billion market opportunity.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Advancing Fluorescence Imaging-guided Partial Nephrectomy with ClearICG
  • 批准号:
    10379857
  • 项目类别:
  • 资助金额:
    $38.53万
  • 财政年份:
    2021
  • 负责人:
    Mengxiao Yu
  • 依托单位:
Advancing Fluorescence Imaging-guided Partial Nephrectomy with ClearICG
  • 批准号:
    10895093
  • 项目类别:
  • 资助金额:
    $85.15万
  • 财政年份:
    2021
  • 负责人:
    Mengxiao Yu
  • 依托单位:
Unravel Nanoparticle Transport and Interactions in Renal Proximal Tubules
  • 批准号:
    10364680
  • 项目类别:
  • 资助金额:
    $28.36万
  • 财政年份:
    2020
  • 负责人:
    Mengxiao Yu
  • 依托单位:
Unravel Nanoparticle Transport and Interactions in Renal Proximal Tubules
  • 批准号:
    10597617
  • 项目类别:
  • 资助金额:
    $27.62万
  • 财政年份:
    2020
  • 负责人:
    Mengxiao Yu
  • 依托单位:
海外基金